Narasimhan Purnima
Birmingham School of Anaesthesia, West Midlands, UK.
Br J Hosp Med (Lond). 2025 Jan 24;86(1):1-4. doi: 10.12968/hmed.2024.0566. Epub 2025 Jan 9.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are emerging as an important class of drugs in the management of Type 2 Diabetes Mellitus (T2DM) and obesity. There are rising concerns of pulmonary aspiration with these medications due to drug-induced gastroparesis. While definitive association is uncertain, it is essential to be prudent and manage these patients as per the current evidence and recommendations.
胰高血糖素样肽-1受体激动剂（GLP-1 RAs）正逐渐成为治疗2型糖尿病（T2DM）和肥胖症的一类重要药物。由于药物引起的胃轻瘫，人们对这些药物导致肺吸入的担忧日益增加。虽然确切的关联尚不确定，但根据目前的证据和建议谨慎处理这些患者至关重要。
